Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Blood

Volumn 123, Issue 10, 2014, Pages 1552-1555

  Rotunno, Giada ^a   Mannarelli, Carmela ^a   Guglielmelli, Paola ^a   Pacilli, Annalisa ^a   Pancrazzi, Alessandro ^a   Pieri, Lisa ^a   Fanelli, Tiziana ^a   Bosi, Alberto ^a   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; ERYTHROPOIESIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; INDEL MUTATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; EXONS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; PREVALENCE; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84897568260     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-538983     Document Type: Article

References (24)

1. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19(10):1847-1849. (Pubitemid 41486170)
2. Campbell PJ, Scott LM, Buck G, et al United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953. (Pubitemid 41713984)
3. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131(2):208-213. (Pubitemid 43899687)
4. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131(3):320-328. (Pubitemid 43899664)
5. Barosi G, Bergamaschi G, Marchetti M, et al; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030-4036. (Pubitemid 350248459)
6. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756-761. (Pubitemid 351559282)
7. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-3476.
8. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al GIMEMA-Italian Registry of Myelofibrosis; MPD Research Consortium. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137(3):244-247. (Pubitemid 46537640)
9. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
10. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
11. Swerdlow SH, Campo E, Harris NL. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues Lyon, France: International Agency for Research on Cancer; 2008.
12. Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933-1940.
13. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
14. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
15. Vannucchi AM, Antonioli E, Guglielmelli P, et al MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952-1959. (Pubitemid 47299969)
16. Pancrazzi A, Guglielmelli P, Ponziani V, et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008;10(5):435-441.
17. Rumi E, Pietra D, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388-4395.
18. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232. (Pubitemid 46218714)
19. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V.F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-846. (Pubitemid 47267419)
20. Barosi G, Mesa RA, Thiele J, et al International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438. (Pubitemid 351250553)
21. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
22. Stein BL, Williams DM, Wang NY, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090-1097.
23. Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis. 2011;2011:874146.
24. Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989-1995.